PFE · Pfizer Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $14.45B | - | $16.65B | $14.65B | $13.71B | - | $17.70B | $13.28B | $14.88B | - |
| Cost of Revenue | $3.55B | - | $4.17B | $3.78B | $2.85B | - | $5.26B | $3.30B | $3.38B | - |
| Gross Profit | $10.90B | - | $12.48B | $10.88B | $10.87B | - | $12.44B | $9.98B | $11.50B | - |
| R&D | $2.49B | - | $2.55B | $2.48B | $2.20B | - | $2.60B | $2.70B | $2.49B | - |
| SG&A | $2.96B | - | $3.19B | $3.42B | $3.03B | - | $3.24B | $3.72B | $3.50B | - |
| Total Operating Expenses | - | - | - | - | - | - | - | - | - | - |
| D&A | $1.61B | - | $1.75B | $1.63B | $1.62B | - | - | - | $1.49B | - |
| Operating Income | $3.17B | - | $3.33B | $3.04B | $2.79B | - | $4.71B | ($103.00M) | $3.42B | - |
| Interest Expense | $668.00M | - | $652.00M | $654.00M | $654.00M | - | $783.00M | $778.00M | $790.00M | - |
| Income Tax | $461.00M | - | ($216.00M) | $141.00M | ($189.00M) | - | $234.00M | ($134.00M) | $293.00M | - |
| Net Income | $2.69B | - | $3.54B | $2.91B | $2.97B | - | $4.46B | $41.00M | $3.12B | - |
| EPS - Basic | $0.47 | - | $0.62 | $0.51 | $0.52 | - | $0.79 | $0.01 | $0.55 | - |
| EPS - Diluted | $0.47 | - | $0.62 | $0.51 | $0.52 | - | $0.78 | $0.01 | $0.55 | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.70B | $1.14B | $1.34B | $1.64B | $1.43B | $1.04B | $1.09B | $1.05B | $719.00M | $2.85B |
| Accounts Receivable | $12.59B | $11.87B | $14.26B | $12.08B | $11.85B | $11.46B | $14.45B | $11.39B | $10.99B | $11.18B |
| Inventory | $10.67B | $10.65B | $11.47B | $11.67B | $10.85B | $10.85B | $11.72B | $11.45B | $10.89B | $10.19B |
| Accounts Payable | $4.51B | $5.24B | $5.02B | $5.17B | $5.24B | $5.63B | $5.31B | $5.11B | $5.59B | $6.71B |
| Current Assets | $42.82B | $42.90B | $46.92B | $43.70B | $45.86B | $50.36B | $43.22B | $37.83B | $42.41B | $43.33B |
| Total Assets | $207.62B | $208.16B | $208.73B | $206.09B | $208.03B | $213.40B | $219.48B | $216.19B | $221.09B | $226.50B |
| Current Liabilities | $34.35B | $36.98B | $36.60B | $37.73B | $36.45B | $42.99B | $43.21B | $43.82B | $40.50B | $47.79B |
| Long-term Debt | $60.56B | $61.64B | $57.41B | $57.50B | $57.64B | $57.41B | $58.00B | $57.51B | $61.31B | $61.54B |
| Total Liabilities | $117.21B | $121.39B | $115.64B | $117.08B | $117.39B | $124.90B | $126.92B | $128.22B | $128.54B | $137.21B |
| Stockholders' Equity | $90.10B | $86.48B | $92.80B | $88.69B | $90.34B | $88.20B | $92.29B | $87.70B | $92.28B | $89.01B |
| Retained Earnings | $117.24B | $114.61B | $121.15B | $117.61B | $119.59B | $116.72B | $121.06B | $116.60B | $121.32B | $118.35B |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $2.62B | - | - | - | $2.33B | - | - | - | $1.09B | - |
| Investing Cash Flow | $785.00M | - | - | - | $3.27B | - | - | - | $1.73B | - |
| Financing Cash Flow | ($2.86B) | - | - | - | ($5.23B) | - | - | - | ($4.93B) | - |
| CapEx | $436.00M | - | - | - | $564.00M | - | - | - | $704.00M | - |
| Free Cash Flow | $2.18B | - | - | - | $1.77B | - | - | - | $386.00M | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 75.4% | - | 74.9% | 74.2% | 79.3% | - | 70.3% | 75.2% | 77.3% | - |
| Operating margin | 21.9% | - | 20.0% | 20.8% | 20.3% | - | 26.6% | -0.8% | 23.0% | - |
| EBITDA margin | 33.1% | - | 30.6% | 31.9% | 32.1% | - | - | - | 33.0% | - |
| Net margin | 18.6% | - | 21.3% | 19.9% | 21.6% | - | 25.2% | 0.3% | 20.9% | - |
| Free cash flow margin | 15.1% | - | - | - | 12.9% | - | - | - | 2.6% | - |
| FCF / Net income | 0.81 | - | - | - | 0.60 | - | - | - | 0.12 | - |
| R&D / Revenue | 17.2% | - | 15.3% | 16.9% | 16.1% | - | 14.7% | 20.3% | 16.8% | - |
| SG&A / Revenue | 20.5% | - | 19.1% | 23.3% | 22.1% | - | 18.3% | 28.0% | 23.5% | - |
| Effective tax rate | 14.6% | - | -6.5% | 4.6% | -6.8% | - | 5.0% | - | 8.6% | - |
| Return on assets | 1.3% | - | 1.7% | 1.4% | 1.4% | - | 2.0% | 0.0% | 1.4% | - |
| Return on equity | 3.0% | - | 3.8% | 3.3% | 3.3% | - | 4.8% | 0.0% | 3.4% | - |
| Return on invested capital | 1.8% | - | 2.2% | 2.0% | 1.9% | - | 3.0% | -0.1% | 2.0% | - |
| Liquidity | ||||||||||
| Current ratio | 1.25 | 1.16 | 1.28 | 1.16 | 1.26 | 1.17 | 1.00 | 0.86 | 1.05 | 0.91 |
| Quick ratio | 0.94 | 0.87 | 0.97 | 0.85 | 0.96 | 0.92 | 0.73 | 0.60 | 0.78 | 0.69 |
| Cash ratio | 0.05 | 0.03 | 0.04 | 0.04 | 0.04 | 0.02 | 0.03 | 0.02 | 0.02 | 0.06 |
| Leverage | ||||||||||
| Debt / Equity | 0.67 | 0.71 | 0.62 | 0.65 | 0.64 | 0.65 | 0.63 | 0.66 | 0.66 | 0.69 |
| Debt / Assets | 0.29 | 0.30 | 0.28 | 0.28 | 0.28 | 0.27 | 0.26 | 0.27 | 0.28 | 0.27 |
| Debt / EBITDA | 12.66 | - | 11.28 | 12.32 | 13.09 | - | - | - | 12.49 | - |
| Interest coverage | 4.7x | - | 5.1x | 4.7x | 4.3x | - | 6.0x | -0.1x | 4.3x | - |
| Equity multiplier | 2.30 | 2.41 | 2.25 | 2.32 | 2.30 | 2.42 | 2.38 | 2.47 | 2.40 | 2.54 |
| Liabilities / Assets | 0.56 | 0.58 | 0.55 | 0.57 | 0.56 | 0.59 | 0.58 | 0.59 | 0.58 | 0.61 |
| Efficiency | ||||||||||
| Asset turnover | 0.07 | - | 0.08 | 0.07 | 0.07 | - | 0.08 | 0.06 | 0.07 | - |
| Inventory turnover | 0.33 | - | 0.36 | 0.32 | 0.26 | - | 0.45 | 0.29 | 0.31 | - |
| Days sales outstanding | 318d | - | 313d | 301d | 315d | - | 298d | 313d | 270d | - |
| Days inventory outstanding | 1097d | - | 1003d | 1127d | 1392d | - | 813d | 1266d | 1177d | - |
| Days payable outstanding | 464d | - | 440d | 499d | 672d | - | 369d | 565d | 604d | - |
| Cash conversion cycle | 952d | - | 876d | 929d | 1035d | - | 742d | 1014d | 842d | - |
| Valuation | ||||||||||
| P / E | 57.5x | - | 38.3x | 47.4x | 48.5x | - | 37.3x | 2798.0x | 50.5x | - |
| P / B | 1.7x | - | 1.5x | 1.6x | 1.6x | - | 1.8x | 1.8x | 1.7x | - |
| P / S | 10.7x | - | 8.2x | 9.4x | 10.5x | - | 9.4x | 12.0x | 10.6x | - |
| EV / EBITDA | 44.7x | - | 37.7x | 41.5x | 45.5x | - | - | - | 44.6x | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 5.4% | - | -5.9% | 10.3% | -7.8% | - | 33.8% | -52.1% | -42.0% | - |
| Revenue CAGR (3y) | -17.4% | - | -9.7% | -19.2% | -18.8% | - | -9.8% | -11.2% | 0.7% | - |
| Revenue CAGR (5y) | -0.2% | - | 6.5% | 4.4% | 2.7% | - | 6.9% | 0.0% | 2.9% | - |
| Gross profit growth (YoY) | 0.3% | - | 0.3% | 8.9% | -5.5% | - | 213.9% | -59.3% | -44.6% | - |
| Operating income growth (YoY) | 13.8% | - | -29.3% | - | -18.6% | - | - | - | -45.4% | - |
| Net income growth (YoY) | -9.4% | - | -20.7% | 6997.6% | -4.8% | - | - | -98.2% | -43.8% | - |
| EPS growth (YoY) | -9.6% | - | -20.5% | 5000.0% | -5.5% | - | - | -97.6% | -43.3% | - |
| EPS CAGR (3y) | -21.5% | - | -25.7% | -33.4% | -27.6% | - | -18.1% | -78.3% | -13.8% | - |
| EPS CAGR (5y) | -11.4% | - | 9.7% | -3.5% | -3.1% | - | -10.5% | -59.3% | -4.2% | - |
| FCF growth (YoY) | 23.0% | - | - | - | 358.8% | - | - | - | 428.8% | - |
| FCF CAGR (5y) | -11.4% | - | - | - | -7.9% | - | - | - | -20.8% | - |
| Book value growth (YoY) | -0.3% | -2.0% | 0.6% | 1.1% | -2.1% | -0.9% | -4.8% | -11.4% | -8.6% | -6.9% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$61.20B totalBiopharma Segment$61.20B · 100.0%
Product / service
$170.36B totalExcluding Comirnaty And Paxlovid$54.47B · 32.0%
Product$51.66B · 30.3%
Eliquis$7.96B · 4.7%
Prevnar Prevenar Family$6.49B · 3.8%
Vyndaqel$6.38B · 3.7%
Comirnaty$4.37B · 2.6%
Ibrance$4.12B · 2.4%
Other Hospital$4.03B · 2.4%
Other Primary Care Products$2.86B · 1.7%
Paxlovid$2.36B · 1.4%
Xtandi$2.19B · 1.3%
Padcev$1.94B · 1.1%
Royalty$1.65B · 1.0%
Other Specialty Care$1.59B · 0.9%
Nurtec ODTVydura$1.42B · 0.8%
Pfizer Centre One$1.34B · 0.8%
Oncology Biosimilars$1.30B · 0.8%
Other Oncology Products$1.13B · 0.7%
Xeljanz$1.09B · 0.6%
Abrysvo$1.03B · 0.6%
Lorbrena$1.02B · 0.6%
Inlyta$923.00M · 0.5%
Adcetris$907.00M · 0.5%
Braftovi Mektovi$716.00M · 0.4%
Sulperazon$653.00M · 0.4%
Inflectra Remsima$646.00M · 0.4%
Zavicefta$638.00M · 0.4%
Enbrel$627.00M · 0.4%
Bosulif$611.00M · 0.4%
Tukysa$463.00M · 0.3%
Aromasin$450.00M · 0.3%
Genotropin$446.00M · 0.3%
Orgovyx$421.00M · 0.2%
Octagam$418.00M · 0.2%
Zithromax Zmax$399.00M · 0.2%
Cresemba$349.00M · 0.2%
FSMEIMMUNTico Vac$319.00M · 0.2%
Elrexfio$304.00M · 0.2%
Cibinqo$284.00M · 0.2%
Talzenna$182.00M · 0.1%
Tivdak$147.00M · 0.1%
Pfizer Ignite$41.00M · 0.0%
Geographic
$62.58B totalUS$37.08B · 59.2%
International Developed Markets$16.19B · 25.9%
International Emerging Markets$9.31B · 14.9%
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing PFIZER INC against the 5 most active filers in the same SIC group.
Dividends
$1.72/share trailing 12 months · +1.2% YoY
| Ex-date | Per share |
|---|---|
| May 8, 2026 | $0.4300 |
| Jan 23, 2026 | $0.4300 |
| Nov 7, 2025 | $0.4300 |
| Jul 25, 2025 | $0.4300 |
| May 9, 2025 | $0.4300 |
| Jan 24, 2025 | $0.4300 |
| Nov 8, 2024 | $0.4200 |
| Jul 26, 2024 | $0.4200 |
| May 9, 2024 | $0.4200 |
| Jan 25, 2024 | $0.4200 |
| Nov 9, 2023 | $0.4100 |
| Jul 27, 2023 | $0.4100 |
| May 11, 2023 | $0.4100 |
| Jan 26, 2023 | $0.4100 |
| Nov 3, 2022 | $0.4000 |
| Jul 28, 2022 | $0.4000 |
| May 12, 2022 | $0.4000 |
| Jan 27, 2022 | $0.4000 |
| Nov 4, 2021 | $0.3900 |
| Jul 29, 2021 | $0.3900 |
| May 6, 2021 | $0.3900 |
| Jan 28, 2021 | $0.3900 |
| Nov 5, 2020 | $0.3605 |
| Jul 30, 2020 | $0.3605 |